(usually about 50-70% objective responses)
Lung metastases of renal cell carcinoma
Huland et al. (1994) J. Cancer Res. Clin. Oncol. 120:221
Huland et al. (1997) Cancer J. Sci. Am..3 Suppl.1 , S68
Huland & Heinzer (2003) Curr. Op. Urol. 13, 451
Huland et al. (2003) Folia Biol (Praha) 49,183
Huland & Heinzer (2004) Curr. Op. Urol. 14, 239
Huland et al. (2004) Urologe A online
Recurrent superficial bladder carcinoma
Tubaro et al. (1995) Eur. Urol. 28, 297
Den Otter et al. (1998) J. Urol. 159, 1183
Grasso et al. (2001) J. Immunother. 24, 184
Nasopharyngeal carcinoma stage III-IV
Jacobs et al. (2005) Cancer Immunol. Immunother. 54, 792
Metastasized melanoma
Radny et al. (2003) Br. J. Cancer 89: 1620-6
Pfoehler et al. (2004) Hautzartz 55:171-5
Green (2007) Br.J.Dermatol. 156:337-4
Human cancer being studied
Therapeutic effect is being studied means less than 10 cases are evaluated, some with positive results
Mesothelioma
Krastev et al. (2001) Cancer Immunol. Immunother. 50, 226
Hepatocellular carcinoma
Krastev et al. (2003) Hepatogastroenterology 50, 1647
Krastev et al. (2005) World J. Gastroenterol. 11, 5525
Colorectal carcinoma
Krastev et al. (2005) World J. Gastroenterol. 11, 5525
Hemangiosarcoma
Krastev et al. (2005) World J. Gastroenterol. 11, 5525
Information for patients
I want to support this research or more information on the EPTI fund supporting this research
Mechanism of IL-2 therapy of cancer
Cancers sensitive to IL-2
Local IL-2 and other therapies:
Surgery and IL-2
Radiotherapy and IL-2
Chemotherapy and IL-2
Experts
Our research group by specialism and by research center
I want to co-operate (doctors)
Frequently Asked Questions (FAQs)
